Search

Your search keyword '"Di Nuzzo, S."' showing total 142 results

Search Constraints

Start Over You searched for: Author "Di Nuzzo, S." Remove constraint Author: "Di Nuzzo, S."
142 results on '"Di Nuzzo, S."'

Search Results

1. Long-Term Drug Survival and Effectiveness of Secukinumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: 42-Month Results from the SUPREME 2.0 Study

2. Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy

3. Long-Term Drug Survival and Effectiveness of Secukinumab in Patients with Moderate to Severe Chronic Plaque Psoriasis: 42-Month Results from the SUPREME 2.0 Study

4. Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: Data from the DA-COVID-19 registry

5. Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy

7. Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 pandemic. risk analysis from the PSO-BIO-COVID observational study

8. Latent tuberculosis infection in patients with chronic plaque psoriasis: evidence from the Italian Psocare Registry*

10. Pruritus characteristics in a large Italian cohort of psoriatic patients

11. Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis. results from extension phase of the SUPREME study

12. AB0578 SUBCLINICAL ENTHESITIS IN PSORIASIS patiEntS AS prediCtor OF ARTHRITIS (EPESCA STUDY): PRELIMINARY RESULTS

13. Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy

20. Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis. SUPREME study

22. A case of acquired disseminated elastosis perforans serpiginosa in a patient with HIV, hepatitis B and hepatitis C successfully treated with narrowband ultraviolet B therapy.

23. Latent tubercolosis infection in patients with cronic plaque psoriasis: evidence from the Italian Psocare Registry

24. Vitiligo management: combination of surgical treatment and phototherapy under reflectance confocal microscopy monitoring.

25. Claimed effects, outcome variables and methods of measurement for health claims proposed under European Community Regulation 1924/2006 in the framework of protection against oxidative damage and cardiovascular health

26. THE ITALIAN MASTOCYTOSIS REGISTRY: THE FIRST FIVE YEARS

27. Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: results from the Italian Psocare registry

29. Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: Evidence from the Italian Psocare Registry

31. UVA1 phototherapy

32. UVA1 phototherapy

34. Favourable effect of alpha-interferon treatment in HBeAb/HBV-DNA positive chronic hepatitis B

35. [Optimization of systemic treatments for chronic plaque psoriasis. Recommendations for switching and transitioning.]

36. Exposure to UVB induces accumulation of LFA-1+ T cells and enhanced expression of the chemokine psoriasin in normal human skin

39. Corrigendum: Sunshine on 'Zebra People'.

40. [Optimization of systemic treatments for chronic plaque psoriasis. Recommendations for switching and transitioning.]

45. Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy

46. Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: Data from the DA-COVID-19 registry

47. Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy

48. Anti-inflammatory effect of ubiquinol-10 on young and senescent endothelial cells via miR-146a modulation

49. Vitiligo Treated with Combined Piperine-Based Topical Treatment and Narrowband Ultraviolet B Therapy: Follow-Up with Reflectance Confocal Microscopy.

50. Dimethyl Fumarate Treatment in Patients with Moderate-to-Severe Psoriasis: A 52-week Real-life Study.

Catalog

Books, media, physical & digital resources